Brain Insulin Sensitivity and Reward Behavior in Mood Disorders
Study Status: active
Institute: Krembil Research Institute
Study Purpose: In this study, we aim to understand how insulin signaling in the brain and in the body can affect anhedonia’s behaviors and brain circuits. A better understanding of the relationship between anhedonia and insulin has the potential to advance further the knowledge on the processes underlying the co-occurrence of mood and metabolic disorders, and to potentially substantiate the development of new preventive and therapeutic interventions.
Background: Depression and metabolic problems, such as diabetes mellitus and obesity are common, impactful and frequently co-occurring medical conditions. Approximately half of the individuals diagnosed with depression have obesity or diabetes; whereas depressive symptoms are among the most frequently reported symptoms in individuals with diabetes mellitus.
Anhedonia, defined as markedly diminished interests or pleasure in all, or almost all, activities, is a common symptom reported by both individuals with depression and metabolic conditions. Anhedonia is typically a very difficult to treat problem and has been associated to poor functional recovery and premature mortality. New approaches to understand anhedonia are urgently needed. Insulin is a hormone which plays a key role in the regulation of blood sugar levels and in the storage of fat. It is prominently involved in conditions such as obesity and diabetes. Evidence from multiple lines of research suggests that insulin might also affect the brain, particularly in the areas involved in the regulation of anhedonia.
Study Methods: In this study, we use functional neuroimaging and intranasal insulin to understand the brain’s unique response to insulin.
Health Conditions:
Mental Health (depression, anxiety, bipolar, etc.)
Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder: A Randomized Clinical Trial
Study Status: completed
Institute: Krembil Research Institute
Study Purpose: This study aimed to assess the safety and efficacy of a weight loss medication, semaglutide, as a treatment for depression.
Background: Cognitive deficits are a core feature of depression. Cognitive impairment is one of the main causes of persistent functional disability in this population. Currently, there are very few treatments that adequately address these cognitive symptoms. Individuals with obesity or metabolic conditions, like diabetes, also frequently report cognitive deficits. Weight-loss interventions, like physical exercise, have been shown to improve cognitive function. Therefore, pharmacological agents that promote weight-loss and/or improvement of metabolic parameters have the potential of being useful at addressing the cognitive problems of individuals with depression. Semaglutide is an anti-diabetes medication that has been approved for weight-loss. Evidence from multiple lines of research has suggested that anti-diabetes medication may improve measures of cognitive function in adults with depression.
Study Methods: This was a 16-week, randomized clinical trial.
Key Findings: Semaglutide was safe for individuals with depression. Semaglutide did not improve executive function; results from secondary analyses suggested effects on specific domains of cognition and motivation. Semaglutide use also resulted in an improvement in quality of life.
Health Conditions:
Mental Health (depression, anxiety, bipolar, etc.)